Therefore, we conducted a systematic review and meta-analysis of SGLT2 inhibitors in randomized controlled trials (RCTs) to assess whether SGLT2 inhibitors could lead to weight loss in adults with overweight or obesity but not diabetes. Here, SLC5A2 is linked to obesity disorder.